NCT00756002View on ClinicalTrials.gov

Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia

PHASE3CompletedINTERVENTIONAL
Enrollment

259

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Sleep Initiation and Maintenance Disorders
Interventions
DRUG

Ramelteon

Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.

DRUG

Placebo

Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY